Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.

Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?

Addus HomeCare

DGX vs. ADUS: Which Stock Is the Better Value Option?

Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.

Quest Diagnostics' New Acquisitions and Pacts Aid Growth

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Why Is Quest Diagnostics (DGX) Down 0.2% Since Last Earnings Report?

Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick Quest Diagnostics (DGX) Stock?

LHC Group

DGX vs. LHCG: Which Stock Is the Better Value Option?

Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2019 Results - Earnings Call Transcript

The laboratory services company beat Wall Street estimates despite reporting only modest revenue growth and another earnings decline.

What You Need to Know About Quest Diagnostics' Q2 Earnings Results

We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.

Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates

Wall Street sees operational improvements accelerating growth, but second quarter results are expected to decline.

Quest Diagnostics Reports Earnings Consolidating a Bear Market Decline

Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.

Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Quest Diagnostics (DGX) Q2 Earnings Expected to Decline

Cooper Companies

Hologic

Women's healthcare gains global importance, investors might want to keep an eye on these stocks.

Women Health a Top Priority Now: 3 Stocks to Watch

Chemed

DGX vs. CHE: Which Stock Is the Better Value Option?

Chairman, President and CEO of Quest Diagnostics Inc (NYSE:DGX) Stephen H Rusckowski sold 244,565 shares of DGX on 06/13/2019 at an average price of $100 a share.

Quest Diagnostics Inc (DGX) Chairman, President and CEO Stephen H Rusckowski Sold $24..

Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.

Here's Why You Should Invest in Quest Diagnostics (DGX) Stock

LabCorp is the latest laboratory testing giant this week to confirm it’s affected by the same third-party data breach.

7.7 million LabCorp records stolen in same hack affecting Quest

Quest Diagnostics Inc said on Monday it was notified by a billing collections vendor that an unauthorized user gained access to information on nearly 11.9 million patients, including credit card numbers and bank account information.

Quest Diagnostics says data breach could have hit nearly 12 million patients

About 11.9 million Quest Diagnostics patients may have had their financial, medical and other personal information exposed in a data breach, the company said Monday.

Quest Diagnostics says nearly 12 million patients may have had data breached

Medical testing giant Quest Diagnostics has confirmed a third-party billing company has been hit by a data breach affecting 11.9 million patients.

Quest Diagnostics says 11.9 million credit cards and medical records skimmed by hackers

Why Is Quest Diagnostics (DGX) Up 3% Since Last Earnings Report?

Quest Diagnostics vs. Chemed

Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Quest Diagnostics (DGX) Jumps: Stock Rises 9.3%

The diagnostics information services company provided an upside surprise on both the top and bottom lines.

Quest Diagnostics Beats Expectations in Q1

Quest Diagnostics' (DGX) CEO Steve Rusckowski on Q1 2019 Results - Earnings Call Transcript

News for Quest Diagnostics Stock (DGX)